生命科学资讯

Lonza Group Continues To Leverage Biopharma’s Optimization Push (OTCMKTS:LZAGY) - Seeking Alpha

'We don't stop': How a new owner is turning around a former Genentech site - The Business Journals

Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks

Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize

Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar

Switzerland’s Lonza edges closer to sale of its capsule and health ingredients business - 93.3 The Drive

Lonza still intends to sell its capsules and health ingredients business - Endpoints News

Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com

Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize

Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters

Lonza delivers strong profitable growth in 2025 - The Pharma Letter

Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Reuters

Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com

Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN

Lonza Sales Grow on New Contract Momentum - The Wall Street Journal

Lonza Sales Grow on New Contract Momentum - The Wall Street Journal

Lonza Sales Grow on New Contract Momentum - The Wall Street Journal

Lonza Sales Grow on New Contract Momentum - The Wall Street Journal

Lonza Sales Grow on New Contract Momentum - The Wall Street Journal